Etirinotecan Pegol vs Physician’s Choice of Chemotherapy for Patients With Metastatic Breast Cancer and Brain Metastases
As reported in JAMA Oncology by Debu Tripathy, MD, and colleagues, the phase III ATTAIN trial has shown no difference in overall survival...
NCCN Clinical Practice Guidelines in Oncology: 2022 Updates
In 1996, the National Comprehensive Cancer Network® (NCCN®) published its first set of Clinical Practice Guidelines in Oncology®...
Medicaid Expansion Is Associated With Increased Survival in Newly Diagnosed Patients With Cancer
A large study led by researchers at the American Cancer Society showed that Medicaid expansion under the Affordable Care Act...
Using a Transcriptomic Profile to Identify Plasma Cell Leukemia–Like Disease in Patients With Newly Diagnosed Multiple Myeloma
In a study reported in the Journal of Clinical Oncology, Bruinink et al constructed a transcriptomic classifier for primary plasma cell leukemia...
ASCO Coronavirus Resources
As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...
Matthew L. Meyerson, MD, PhD, on Lung Adenocarcinoma: Somatic Mutations, Germline Risk, and Ancestry
Louis Staudt and Wyndham Wilson: Phase III Trials and Tribulations
Lisa Carey: Immune Checkpoint Inhibitors in Neoadjuvant or Adjuvant Therapy for TNBC
Rachel Grisham: MEK Inhibition Is Now a Standard of Care in Recurrent Low-Grade Serous Ovarian Cancer
James Smithy and Margaret Callahan: Relatlimab Plus Nivolumab Worthy of Further Study in Advanced Melanoma and Beyond
Neal Meropol: Reflections on the Evolution of Clinical Care Since the Passage of the National Cancer Act
Sponsored Content
Sponsored by Iovance Biotherapeutics
Emerging Cell-Based Therapies for Non–Small Cell Lung Cancer
Sponsored by Adaptive Biotechnologies
The Role of Minimal Residual Disease Assessment in Guiding Personalized Care in Multiple Myeloma
Sponsored by Pfizer Medical Affairs
Considerations in the Front-Line Treatment of Hormone Receptor–Positive/HER2-Negative Advanced Breast Cancer
Pralsetinib in Advanced RET Fusion–Positive NSCLC: ARROW Trial
As reported in The Lancet Oncology by Justin F. Gainor, MD, and colleagues, an interim analysis of the phase I/II ARROW trial has shown that the oral RET inhibitor pralsetinib produced high response rates in previously treated and treatment-naive patients with advanced RET fusion–positive non–small ...
Impact of Genes on Total Number and Type of Nevi
A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer. “The goal was to investigate the genetic underpinnings of different mole classes, or...
PET Response–Adapted Chemoradiotherapy for Esophageal and Esophagogastric Junction Adenocarcinoma
As reported in the Journal of Clinical Oncology by Karyn A. Goodman, MD, and colleagues, mature results of the phase II CALGB 80803/Alliance trial indicated that treatment guided by early positron-emission tomography (PET) assessment of response to induction neoadjuvant chemotherapy improved...
Nearly Half of Surveyed Patients With Gynecologic Cancer Report Experiencing Financial Toxicity
In a new study designed to provide a more comprehensive picture of how a diverse cohort of patients with gynecologic cancer are affected by financial distress, nearly half reported financial toxicity, which was associated with economic cost-coping strategies. These findings were reported by Esselen ...
Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma
In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...
Remote Monitoring Program Reduced Hospitalization Among Patients With Cancer Infected With COVID-19
A study by researchers at Mayo Clinic Cancer Center found that patients with cancer diagnosed with COVID-19 who received care at home via remote patient monitoring were significantly less likely to require hospitalization for their illness, compared to patients with cancer infected with the virus...
Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...
